Carcinoma of unknown primary (CUP); some considerations about pathogenesis and diagnostic strategy, particularly focusing on CUPS pertaining to the Urology
- PMID: 22357439
Carcinoma of unknown primary (CUP); some considerations about pathogenesis and diagnostic strategy, particularly focusing on CUPS pertaining to the Urology
Abstract
The term "carcinoma of unknown primary" (CUP) defines a malignant condition in which a metastatic cancer is documented in absence of a detectable primary site. It occurs in about 2÷6 % of cancer patients, according to various literature reports. The primary tumor site results indefinable because of several either single or associated factors, even remaining occult at autopsy in 15÷25% of CUP patients. The metastatic spread pattern of CUP is quite unlike that expected for analogous known primary malignancy. For instance, the unknown prostate cancer often metastasizes to the lungs and liver while the its known analogous usually spreads to the bone. Whether certain genetic abnormalities might play a role in determining a CUP condition, it remains undefined. Most CUP are adenocarcinoma, squamous cell carcinoma, either undifferentiated or differentiated carcinoma, whereas less frequently may be sarcoma, melanoma or neuroendocrine tumor. As CUP diagnostic management is concerned, two opposite approach modalities may be adopted, one, named "shotgun modality", consisting in a multiplicity of examinations aimed at achieving the identification of the primary tumor and the other, a nihilistic modality, by adopting tout court a palliative therapy of the metastatic disease. A reasonable intermediate diagnostic strategy consists in undertaking some procedures with a specific target and low cost/benefit ratio. Selected imaging studies, serum tumor markers, immunohistochemical analyses and genetic- molecular examinations on biopsy material allow sometimes to reach the detection of primary malignancies that might be responsive to a potential treatments. Nevertheless, in spite of recent sophisticated -laboratory and imaging progress, CUP remains a strong challenge in clinical oncology.
Similar articles
-
Carcinoma of unknown primary (CUP).Crit Rev Oncol Hematol. 2009 Mar;69(3):271-8. doi: 10.1016/j.critrevonc.2008.09.005. Epub 2008 Nov 1. Crit Rev Oncol Hematol. 2009. PMID: 18977667 Review.
-
[Cancer of unknown primary site origin--advances in diagnosis and therapy].Harefuah. 2008 Apr;147(4):294-8, 376, 375. Harefuah. 2008. PMID: 18686808 Hebrew.
-
[Treatment of cancer of unknown primary, today and future].Gan To Kagaku Ryoho. 2009 Jun;36(6):918-22. Gan To Kagaku Ryoho. 2009. PMID: 19542712 Japanese.
-
[CUP syndrome: are there advances?].Verh Dtsch Ges Pathol. 2005;89:125-36. Verh Dtsch Ges Pathol. 2005. PMID: 18035682 German.
-
Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site.Semin Oncol. 1993 Jun;20(3):279-86. Semin Oncol. 1993. PMID: 8503024 Review.
Cited by
-
A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.BMC Res Notes. 2014 Jan 29;7:64. doi: 10.1186/1756-0500-7-64. BMC Res Notes. 2014. PMID: 24476098 Free PMC article.
-
Granulocyte colony-stimulating factor-producing carcinoma of unknown primary site.Case Rep Oncol. 2014 Nov 22;7(3):780-8. doi: 10.1159/000369335. eCollection 2014 Sep-Dec. Case Rep Oncol. 2014. PMID: 25722669 Free PMC article.
-
Carcinoma of unknown primary site treated with Carboplatin + Paclitaxel + bevacizumab + erlotinib and its maintenance chemotherapy.Case Rep Oncol. 2014 Aug 20;7(2):583-90. doi: 10.1159/000366268. eCollection 2014 May. Case Rep Oncol. 2014. PMID: 25298764 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials